• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Imprimis acquires intellectual property for drug candidate

Imprimis acquires intellectual property for drug candidate

July 26, 2013
CenterWatch Staff

Imprimis Pharmaceuticals, which focuses on the commercialization of drug formulations utilizing the FDA drug development pathway, has acquired intellectual property for IPI-120, a novel drug formulation of both tranexamic acid, a synthetic derivative of the amino acid lysine, and an antibiotic. The company's recently-filed patent application combines tranexamic acid with an antibiotic to provide the clotting effects along with protection or treatment against infection in a transdermal, local intra-wound application or intra-cavity instillation formulation.

IPI-120 could help patients with genetic and acquired bleeding disorders. Lower strength IPI-120 formulations for OTC applications may also be used to stop bleeding and prevent or treat infection in common wounds, cuts and bruises.

Tranexamic acid, which is approved in intravenous and oral dosage forms, is frequently used in surgeries with high risk of blood loss such as cardiac, liver, vascular and large orthopedic procedures. Imprimis believes IPI-120 may be applied in targeted compromised populations of patients with bleeding disorders and may qualify as an orphan drug development candidate. IPI-120 was created by a pharmacist at Buderer Drug, a compounding pharmacy in Ohio, interested in offering a transdermal wound management product that not only acted as an antibiotic, but that also helped control bleeding.

"Control of bleeding and infection is an integral part of the wound healing process,” said Dr. Joachim Schupp, Imprimis’ chief medical officer. “The normal blood clotting process depends on the interplay of various proteins in the blood. Bleeding disorders may be caused by reduced levels or absence of blood-clotting proteins, known as clotting factors or coagulation factors. A reduction in those clotting factors is found in genetic disorders, such as hemophilia A, hemophilia B and von Willebrand disease. Bleeding disorders can also be acquired such as in end stage liver disease, acute leukemia or Vitamin K deficiency.”

The U.S. wound care market is expected to reach nearly $21 billion by 2015, from $16.8 billion in 2012. Seven million Americans suffer from chronic wounds and the market is expected to grow in part due to the aging population and ongoing proliferation of diabetes and other chronic illnesses.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing